The Development of ADS-5102 (Amantadine ER Capsules) for the Treatment of Levodopa-induced Dyskinesia

被引：0
作者：
McClure, Natalie [1 ]
机构：
[1] Adamas Pharmaceut Inc, Emeryville, CA USA
来源：
NEUROTHERAPEUTICS | 2015年 / 12卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：679 / 680
页数：2
相关论文
共 50 条
  • [1] ADS-5102 (Amantadine) Extended Release for Levodopa-Induced Dyskinesia
    Pahwa, Rajesh
    Hauser, Robert A.
    JAMA NEUROLOGY, 2017, 74 (12) : 1507 - 1508
  • [2] ADS-5102 (Amantadine) Extended Release for Levodopa-Induced Dyskinesia Reply
    Shukla, Aparna Wagle
    JAMA NEUROLOGY, 2017, 74 (12) : 1508 - 1508
  • [3] Efficacy and safety of ADS-5102 (amantadine) extended-release capsules for treating levodopa-induced dyskinesia
    Agarwal, Pinky
    Ray, Sudeshna
    Burdick, Daniel
    Griffith, Alida F.
    Madan, Arina
    EXPERT OPINION ON ORPHAN DRUGS, 2018, 6 (10): : 625 - 634
  • [4] ADS-5102 (amantadine HCl) extended-release capsules reduced levodopa-induced dyskinesia in the phase 3 EASE LID study
    Pahwa, R.
    Tanner, C. M.
    Hauser, R. A.
    Nausieda, P.
    Truong, D. D.
    Hull, K.
    Agarwal, P.
    Johnson, R.
    Ruby, A. E.
    McClure, N. L.
    Stempien, M. J.
    MOVEMENT DISORDERS, 2016, 31 : S663 - S663
  • [5] ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study) A Randomized Clinical Trial
    Pahwa, Rajesh
    Tanner, Caroline M.
    Hauser, Robert A.
    Isaacson, Stuart H.
    Nausieda, Paul A.
    Truong, Daniel D.
    Agarwal, Pinky
    Hull, Keith L.
    Lyons, Kelly E.
    Johnson, Reed
    Stempien, Mary Jean
    JAMA NEUROLOGY, 2017, 74 (08) : 941 - 949
  • [6] Pooled Analysis of Phase 3 Studies of ADS-5102 (Amantadine) Extended Release Capsules for Levodopa-Induced Dyskinesia: A Detailed Review of UDysRS Results
    Pahwa, Rajesh
    Hauser, Robert
    Tanner, Caroline
    Isaacson, Stuart
    Johnson, Reed
    Felt, Larissa
    Patni, Rajiv
    ANNALS OF NEUROLOGY, 2017, 82 : S86 - S86
  • [7] Pooled Analysis of Phase 3 studies of ADS-5102 (amantadine hydrochloride) extended release capsules for Levodopa-Induced Dyskinesia: A detailed review of UDysRS Results
    Pahwa, Rajesh
    Tanner, Caroline
    Hauser, Robert
    Isaacson, Stuart
    Johnson, Reed
    Felt, Larissa
    Stempien, Mary Jean
    NEUROLOGY, 2017, 88
  • [8] Pharmacokinetics of ADS-5102 (Amantadine) ExtendedRelease Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia
    Hauser, Robert A.
    Pahwa, Rajesh
    Wargin, William A.
    Souza-Prien, Cindy J.
    McClure, Natalie
    Johnson, Reed
    Nguyen, Jack T.
    Patni, Rajiv
    Went, Gregory T.
    CLINICAL PHARMACOKINETICS, 2019, 58 (01) : 77 - 88
  • [9] Randomized, Placebo-Controlled Trial of ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 3)
    Oertel, Wolfgang
    Eggert, Karla
    Pahwa, Rajesh
    Tanner, Caroline M.
    Hauser, Robert A.
    Trenkwalder, Claudia
    Ehret, Reinhard
    Azulay, Jean Philippe
    Isaacson, Stuart
    Felt, Larissa
    Stempien, Mary Jean
    MOVEMENT DISORDERS, 2017, 32 (12) : 1701 - 1709
  • [10] Rater training and data completeness in the study of ADS-5102 in levodopa-induced dyskinesia (EASED study)
    Stempien, M. J.
    Hauser, R. A.
    Brady, C.
    Ruby, A. E.
    McClure, N. L.
    Goetz, C. G.
    MOVEMENT DISORDERS, 2014, 29 : S268 - S268
12345